Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7502564 | 0.80 | ALDH1A1 (0.53) | CNR2HTR1A | |
| SCHEMBL4831587 | 0.79 | CNR2 (0.41) | MGLLOPRM1OPRK1CNR2 | |
| SCHEMBL6327807 | 0.78 | GSK3B (0.44) | MGLLOPRM1OPRK1CNR2 | |
| SCHEMBL4529633 | 0.78 | PTPN1 (0.54) | MGLLOPRM1OPRK1CNR2HTR1A | |
| SCHEMBL14380682 | 0.78 | CNR2 (0.41) | MGLLOPRM1OPRK1CNR2 | |
| SCHEMBL6337807 | 0.78 | CNR2 (0.41) | MGLLOPRM1OPRK1CNR2 | |
| SCHEMBL6327050 | 0.76 | ALDH1A1 (0.40) | MGLLOPRM1OPRK1CNR2HTR1A | |
| SCHEMBL4097659 | 0.74 | PTPN1 (0.59) | — | |
| SCHEMBL17023632 | 0.74 | HSD17B10 (0.56) | CNR2HTR1A | |
| SCHEMBL2083799 | 0.73 | NR4A1 (0.48) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900216-B2 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2005-05-31 | — | — | US | disclosed |
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | KNOLL GMBH (DE) | 2003-09-04 | — | — | US | disclosed |
| EP-1268489-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | Knoll GmbH (DE) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001068653-A1 | DIHYDROIMIDAZO[2,1-B]THIAZOLE AND DIHYDRO-5H-THIAZOLO[3,2-A]PYRIMIDINES AS ANTIDEPRESSANT AGENTS | KNOLL GMBH (DE) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166628-A1 | Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-A]pyrimidines as antidepressant agents | GPR119, HTR3B, HTR2B | MGLL 3579/4885OPRM1 291/4885OPRK1 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.